Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Barkin

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
European Urology|October 15, 2009
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyClaus G Roehrborn, Paul Siami, Jack Barkin, et al.
European Urology|January 10, 2017
Corrigendum to "The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study" [Eur Urol 2010;57:123-31]Claus G Roehrborn, Paul Siami, Jack Barkin, et al.
BJU International|April 26, 2014
Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaAnthony L Cantwell, William K Bogache, Steven F Richardson, et al.
The Journal of Urology|March 23, 2010
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trialSender Herschorn, Lynn Stothers, Kevin Carlson, et al.
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Clinical Therapeutics|November 18, 2005
Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysisDimitrios G Hatzichristou, Philip Aliotta, Stephen Auerbach, et al.
Urology|April 19, 2005
Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitisJ Curtis Nickel, Jack Barkin, John Forrest, et al.
BJU International|September 30, 2016
24-month durability after crossover to the prostatic urethral lift from randomised, blinded shamDaniel Rukstalis, Prem Rashid, William K Bogache, et al.
Urology|March 7, 2002
Effect of pentosan polysulfate therapy on intravesical potassium sensitivityC Lowell Parsons, John Forrest, J Curtis Nickel, et al.
The Journal of Urology|June 7, 2006
Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuriaMichael F Sarosdy, Paul R Kahn, Mark D Ziffer, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
European Urology|October 15, 2009
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyClaus G Roehrborn, Paul Siami, Jack Barkin, et al.
European Urology|January 10, 2017
Corrigendum to "The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study" [Eur Urol 2010;57:123-31]Claus G Roehrborn, Paul Siami, Jack Barkin, et al.
BJU International|April 26, 2014
Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaAnthony L Cantwell, William K Bogache, Steven F Richardson, et al.
The Journal of Urology|March 23, 2010
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trialSender Herschorn, Lynn Stothers, Kevin Carlson, et al.
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Clinical Therapeutics|November 18, 2005
Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysisDimitrios G Hatzichristou, Philip Aliotta, Stephen Auerbach, et al.
Urology|April 19, 2005
Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitisJ Curtis Nickel, Jack Barkin, John Forrest, et al.
BJU International|September 30, 2016
24-month durability after crossover to the prostatic urethral lift from randomised, blinded shamDaniel Rukstalis, Prem Rashid, William K Bogache, et al.
Urology|March 7, 2002
Effect of pentosan polysulfate therapy on intravesical potassium sensitivityC Lowell Parsons, John Forrest, J Curtis Nickel, et al.
The Journal of Urology|June 7, 2006
Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuriaMichael F Sarosdy, Paul R Kahn, Mark D Ziffer, et al.
Pageof 11